openPR Logo
Press release

Investigation announced for Investors in AbbVie Inc. (NYSE: ABBV) concerning potential Wrongdoing

07-01-2022 04:23 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Shareholders Foundation

An investigation on behalf of current long term investors in AbbVie Inc. (NYSE: ABBV) shares over possible breaches of fiduciary d

An investigation on behalf of current long term investors in AbbVie Inc. (NYSE: ABBV) shares over possible breaches of fiduciary d

An investigation was announced for long-term investors in shares of AbbVie Inc. (NYSE: ABBV) concerning potential breaches of fiduciary duties by certain directors of AbbVie Inc..

Investors who are current long term investors in AbbVie Inc. (NYSE: ABBV) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.

The investigation by a law firm for current long term investors in NYSE: ABBV stocks follows a lawsuit filed against AbbVie Inc. over alleged securities laws violations. The investigation on behalf of current long term investors in NYSE: ABBV stocks, concerns whether certain AbbVie Inc. directors are liable in connection with the allegations made in that lawsuit.

According to that complaint filed in the U.S. District Court for the Northern District of Illinois the plaintiff alleges that the Defendants misrepresented and/or failed to disclose that safety concerns about Xeljanz extended to Rinvoq and other JAK inhibitors, that as a result, it was likely that the FDA would require additional safety warnings for Rinvoq and would delay the approval of additional treatment indications for Rinvoq, and that therefore, Defendants' statements about the company's business, operations, and prospects lacked a reasonable basis, As a result of the Defendants' wrongful acts and omissions, and the significant decline in the market value of AbbVie's securities, AbbVie investors have suffered significant damages.

Those who purchased shares of AbbVie Inc. (NYSE: ABBV) have certain options and should contact the Shareholders Foundation.

Contact:
Christopher Clausen
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com

About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities lawsuits, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Investigation announced for Investors in AbbVie Inc. (NYSE: ABBV) concerning potential Wrongdoing here

News-ID: 2668455 • Views:

More Releases from Shareholders Foundation

Investigation announced for Long-Term Investors in shares of West Pharmaceutical Services, Inc. (NYSE: WST) over potential Wrongdoing
Investigation announced for Long-Term Investors in shares of West Pharmaceutical …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of West Pharmaceutical Services, Inc.. Investors who are current long term investors in West Pharmaceutical Services, Inc. (NYSE: WST) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in (NYSE: WST stocks follows a lawsuit filed
Investigation announced for Long-Term Investors in Open Lending Corporation (NASDAQ: LPRO) over potential Wrongdoing
Investigation announced for Long-Term Investors in Open Lending Corporation (NAS …
An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of Open Lending Corporation. Investors who are current long term investors in Open Lending Corporation (NASDAQ: LPRO) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm for current long term investors in NASDAQ: LPRO stocks follows a lawsuit filed against Open
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings, Inc. (NYSE: BBAI)
Investigation announced for Long-Term Investors in shares in BigBear.ai Holdings …
An investigation on behalf of current long-term investors in shares of BigBear.ai Holdings, Inc. (NYSE: BBAI) concerning potential breaches of fiduciary duties by certain directors and officers of BigBear.ai Holdings, Inc. was announced. Investors who are current long term investors in BigBear.ai Holdings, Inc. (NYSE: BBAI) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554. The investigation by a law firm
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, Inc. (NYSE: DV)
Lawsuit filed for Investors who lost money with shares of DoubleVerify Holdings, …
An investor, who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV), filed a lawsuit over alleged violations of Federal Securities Laws by DoubleVerify Holdings, Inc. in connection with certain allegedly false and misleading statements. Investors who purchased shares of DoubleVerify Holdings, Inc. (NYSE: DV) have certain options and for certain investors are short and strict deadlines running. Deadline: July 21, 2025. NYSE: DV investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com

All 5 Releases


More Releases for AbbVie

Endometriosis Market Predicted to See Upsurge Through 2034, Highlights DelveInsi …
The Key Endometriosis Companies in the market include - AbbVie, Myovant, Pfizer, AbbVie, Neurocrine Biosciences, ObsEva, Kissei Pharmaceuticals, Enteris BioPharma Inc., Spago Nanomedical AB, Iqvia Pty Ltd, Nanjing Chia-tai Tianqing Pharmaceutical, Myovant Sciences GmbH, Hope Medicine (Nanjing) Co., Ltd, Ferring Pharmaceuticals, Jiangsu HengRui Medicine, ObsEva, AbbVie, ASKA Pharmaceutical Co., Ltd., Abbott, Kissei Pharmaceutical Co., Ltd., Bayer, Pfizer, and others. DelveInsight's "Endometriosis Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth
The Future of Refractory Multiple Myeloma Therapy: 75+ Companies Advancing the C …
Pharmaceutical pioneers are unlocking new opportunities in Refractory Multiple Myeloma treatment for metabolic disorders. DelveInsight's 'Refractory Multiple Myeloma Pipeline Insight 2024' report provides comprehensive global coverage of pipeline Refractory Multiple Myeloma therapies in various stages of clinical development. Major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Refractory Multiple Myeloma pipeline domain. For Refractory Multiple Myeloma emerging drugs, the Refractory Multiple Myeloma pipeline analysis report
Pouchitis Treatment Market | AbbVie, Alfasigma, Astellas Pharma, AstraZeneca
The global pouchitis treatment market report is a comprehensive report that provides a detailed analysis of the current status and future trends of the pouchitis treatment market worldwide. This report provides valuable information to industry stakeholders by offering an in-depth perspective on market dynamics, competitive landscape, growth opportunities, and key challenges faced by industry participants. From the perspective of market dynamics, this report explores the factors driving the growth of the
Biopharmaceuticals Market Worth Observing Growth: Johnson & Johnson, Roche, AbbV …
Latest Market intelligence report released by HTF MI with title "Global Biopharmaceuticals Market Report 2020 by Key Players, Types, Applications, Countries, Market Size, Forecast to 2026 (Based on 2020 COVID-19 Worldwide Spread)" is designed covering micro level of analysis by manufacturers and key business segments. The Global Biopharmaceuticals Market survey analysis offers energetic visions to conclude and study market size, market hopes, and competitive surroundings. The research is derived through
Leukemia Therapeutics Market Worth Observing Growth | Pfizer, Sanofi, AbbVie
Latest publication on 'Global Leukemia Therapeutics Market – By Disease Type (Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Acute Lymphocytic Leukemia, and Acute Myeloid Leukemia), By Drug Class (Small Molecules and Biologics), and By Regions (North America, Europe, Asia Pacific, and Rest of the World): Forecast up to 2025' is added in HTF MI research reporsitory provides in-depth analysis, Competitive scenario, and future market trends and strategies. The regional analysis
Immunotherapy Drugs Market Next Big Thing | Amgen, GlaxoSmithKline, AbbVie
AMA Research added a comprehensive research document of 200+ pages on 'Immunotherapy Drugs' market with detailed insights on growth factors and strategies. The study segments key regions that includes North America, Europe, Asia-Pacific with country level break-up and provide volume* and value related cross segmented information by each country. Some of the important players from a wide list of coverage used under bottom-up approach are: F. Hoffmann-La Roche AG (Switzerland)